CHMP Approves Ivermectin/Albendazole Combination for Parasitic Worm Infections
Alejandro Krolewiecki, MD On January 30, 2025, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for the approval of Ivermectin/Albendazole, a fixed-dose combination aimed at treating soil-transmitted helminth infections and microfilaraemia in lymphatic filariasis patients. This marks an important step forward in combating parasitic worm infections, particularly in regions outside […]
Emerging Threats and Key Knowledge from 2024 Leading into 2025
Clinical science in infectious diseases saw significant progress in 2024, with multiple clinical trials of new antibiotics and infection prevention strategies. The year also brought public health challenges, including outbreaks of dengue, measles, mpox, and highly pathogenic avian influenza A, highlighting the continued need for research and clinical interventions. At IDWeek 2024, experts gathered to […]
Indoor Domestic Cats Within Dairy Worker Households Contract Avian Influenza
It has been previously documented that outdoor cats on dairy farms have contracted HPAI A(H5N1), otherwise known as avian influenza; however, up until now, the virus has not been reported in indoor cats. In this week’s Morbidity and Mortality Weekly Report (MMWR), published by the Centers for Disease Control and Prevention (CDC), avian influenza was […]
High Uptake for RSV Vaccine and Nirsevimab Among Pregnant Women, Infants
Amongst eligible pregnant women, 64.0% received the RSVpreF vaccine, and 70.1% of eligible neonates received nirsevimab, according to a new study that was published in JAMA Network Open, yesterday. The investigators write that this translates to more than 80% coverage against RSV during all but the first month of the study.1 “This study suggests that […]
Ginkgo Bioworks Targets Infectious Disease with Rapid Respiratory Virus Detection System
Ginkgo Bioworks is collaborating with the European Health and Digital Executive Agency (HaDEA) in a project valued at up to €24 million to develop rapid metagenomic sequencing for respiratory virus detection. The funding comes from the EU4Health program and aligns with the priorities of the Health Emergency Preparedness and Response Authority (HERA). The RANGER (RApid […]
Paxlovid Does Not Significantly Reduce COVID-19 Hospitalization, Mortality in Vaccinated Older Adults
In a large study published today, nirmatrelvir-ritonavir (Paxlovid) use was not found to reduce hospitalizations and mortality in adults 70 years of age and older who were vaccinated.1 “There were no significant differences just below vs just above age 70 years (per 100000 patients per month) in COVID-19–related hospitalizations (39.5 vs 42.9; absolute difference, 3.4; […]
Persistent Fever as a Key Mortality Predictor in MRSA Bacteremia
Sean Ong Image credits: LinkedIn A post hoc analysis of the CAMERA2 randomized clinical trial has identified persistent fever after 72 hours as a key predictor of increased mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. In contrast, white blood cell (WBC) count and C-reactive protein (CRP) levels did not show the same predictive […]
Monoclonal Antibody Reduces Mortality for SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) is a severe lung condition that causes fluid to build up in the lungs leading to difficulty breathing, shortness of breath, confusion, and dizziness and decompensate into complications such as blood clots and infections.1,2 About 25% to 40% of people with ARDS do not survive, even with treatment, which […]
Addressing the Threat of Candida Infections: Resistance and Management
Oliver Cornely Image credits: CECAD Cologne Candida species are the leading cause of fungal infections in hospitalized patients, contributing significantly to morbidity and mortality. Invasive candidiasis, including candidemia, primarily affects immunocompromised or critically ill individuals, while mucocutaneous candidiasis, such as oral thrush and vulvovaginal candidiasis, can occur in otherwise healthy individuals. While mucocutaneous forms are […]
Recce Pharmaceuticals Reports Positive Data from Phase 2 Study for Gel for ABSSSI
Image credit: Recce Pharmaceuticals Sydney, Australia-based Recce Pharmaceuticals reported positive findings from its phase 2 study examining the efficacy and safety of its topical gel, R327G (RECCE 327), in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections (DFI). R327G demonstrated a 93% primary efficacy endpoint over 14 […]
